Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
Pharmaceutical Executive July 10, 2014 Fitzpatrick & Mohan	Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
BusinessWeek April 26, 2004 Kerry Capell	Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
HBS Working Knowledge February 28, 2005 Cynthia Churchwell	Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution.
Pharmaceutical Executive September 1, 2006 Kieran Hartsough	Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside.
Scientific American July 2006 JR Minkel	Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive.
Bio-IT World Dec 2005/Jan 2006 Salvatore Salamone	Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises.
Pharmaceutical Executive September 1, 2011	The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
BusinessWeek January 29, 2007 Kerry Capell	GlaxoSmithKline: Getting AIDS Drugs To More Sick People GlaxoSmithKline sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world.
American Family Physician December 1, 2002 Sanford R. Kimmel	Vaccine Adverse Events: Separating Myth from Reality Vaccines have turned many childhood diseases into distant memories in industrialized countries. However, questions have been raised about the safety of some vaccines because of rare but serious adverse effects that have been attributed to them.
Pharmaceutical Executive September 1, 2006 Jill Wechsler	Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world.
Chemistry World March 17, 2011 Hepeng Jia	International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation.
Finance & Development December 1, 2007	Is the Global Health System Broken Three points of view on how the global health system can be improved: Making Markets Work by Joe Cerrell... Finding a Unified Vision by Helen Gayle and J. Stephen Morrison... Targeting the Health MDGs by Tore Godal...
Pharmaceutical Executive December 1, 2005 Sarah Houlton	Global Report: Wanted: Attention Bird flu is number one on the media's agenda. But other diseases need better immunization, too. WHO estimates that in 2002, 2.1 million people died from diseases that could have been prevented by vaccines that WHO currently recommends.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Managed Care October 2000 Kevin A. Wilson	Public Policy Largely Ignores Adult Immunization Needs Although four fifths of the nation's children are fully immunized, tens of thousands of adults die each year from diseases preventable by vaccination...
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
Chemistry World January 19, 2015 Maria Burke	Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine.
Salon.com March 8, 2001 Amy Standen	Ready for some lockjaw? There's no profit in the tetanus vaccine business, so a rare and hideous disease may soon strike more Americans...
Chemistry World July 29, 2015 Maria Burke	Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear.
The Motley Fool March 9, 2010 Brian Orelli	Are Billions of Dollars in Revenue at Risk? Vaccine makers' lawsuit protection is called into question.
American Family Physician May 15, 2001	Pneumococcal Conjugate Vaccine: What a Parent Needs to Know Why should my child get this vaccine?... What exactly is the pneumococcal vaccine?... Are there some children who should not get pneumococcal conjugate vaccine or who should wait until they are older?...
BusinessWeek October 22, 2007 Catherine Arnst	Roll Up Your Sleeve, Gramps A graying population may create a huge market for vaccines that buttress aging immune systems.
Smithsonian November 2005	35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world.
Pharmaceutical Executive June 1, 2005 Seth Berkley	Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
BusinessWeek November 18, 2010 Jason Gale	Bill Gates' Latest Challenge: Polio Bill Gates is brokering deals with drugmakers to make cheaper vaccines available.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
Salon.com December 15, 2000 Arthur Allen	Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research...
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources.
The Motley Fool October 26, 2011 Chris Baines	Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Managed Care January 2008 Martin Sipkoff	Should Pharmacists Be Allowed To Vaccinate Their Patients? Although federal health agencies support the idea of having pharmacists administer vaccines to their patients, the roadblock continues to be a question of payment.
Fast Company November 2002 Chuck Salter	Richard Klausner Spends to Save Lives At the wealthiest foundation on the planet, a brilliant scientist is giving away Bill Gates's money in pursuit of a lofty goal: solving the world's most pressing health problems.
Finance & Development December 1, 2007 David E. Bloom	Governing Global Health How better coordination can advance global health and improve value for money.
Pharmaceutical Executive October 1, 2014 Jill Wechsler	Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak.
Bio-IT World June 15, 2003 Malorye Branca	A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery?
Pharmaceutical Executive October 1, 2011 William Looney	Partnering with the New Players Carlos Morel has been closely associated with the Oswaldo Cruz Foundation from the start of his career and now holds a pivotal role in creating a new infrastructure to support translational research on diseases critical to Brazil and other emerging country markets.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
Finance & Development December 1, 2007 Arvind Subramanian	Harnessing Ideas to Idealism A profile of Michael Kremer, the Gates Professor of Developing Societies at Harvard University, whose economic ideas are motivated by idealism and then pursued with intense commitment.
BusinessWeek January 8, 2007 Arlene Weintraub	Making Her Mark At Merck Margaret McGlynn, critical to a post-Vioxx turnaround, is on a fast track.
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
American Family Physician July 1, 2004 Lo Re & Gluckman	Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases.